GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

医学 肝硬化 疾病 脂肪肝 内科学 肝病 胃肠病学
作者
Fasiha Kanwal,Jennifer R. Kramer,Liang Li,Yu‐Xiao Yang,Yumei Cao,Xian Yu,Ronald Samuel,Basim Ali,Roxanne Desiderio,George Cholankeril,Mandeep Bajaj,Hashem B. El‐Serag,Steven M. Asch
出处
期刊:JAMA Internal Medicine [American Medical Association]
标识
DOI:10.1001/jamainternmed.2024.4661
摘要

Importance Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing cause of cirrhosis. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are effective in improving liver inflammation in patients with MASLD. Objective To determine whether use of GLP-1 RAs is associated with lower risk of developing cirrhosis and its complications, including decompensation and hepatocellular cancer (HCC), among patients with MASLD. Design, Setting, and Participants This retrospective cohort study with an active comparator, new-user design used data from the national Veterans Health Administration Corporate Data Warehouse and Central Cancer Registry. Patients with MASLD and diabetes who were seen at 130 Veterans Health Administration hospitals and associated ambulatory clinics and who initiated either a GLP-1 RA or dipeptidyl peptidase 4 inhibitor (DPP-4i) between January 1, 2006, and June 30, 2022, were included. Patients were followed up from baseline until one of the study outcomes or the end of the study period (December 31, 2022), whichever came first. Exposures Each GLP-1 RA new user was propensity score matched in 1:1 ratio to a patient who initiated a DPP-4i during the same month. Separate analyses were conducted among patients without and with cirrhosis at baseline. Main Outcomes and Measures For patients without cirrhosis, the primary outcome was progression to cirrhosis defined by validated diagnoses codes or a noninvasive marker of liver fibrosis, and secondary outcomes were cirrhosis complications defined both as a composite and individual complications, including decompensation, HCC, or liver transplant, and all-cause mortality. For patients with cirrhosis, the primary outcome was a composite outcome of cirrhosis complications, and secondary outcomes were decompensation, HCC, and all-cause mortality. Results Of 16 058 patients who initiated GLP-1 RAs, 14 606 did not have cirrhosis (mean [SD] age, 60.56 [10.31] years; 13 015 [89.1%] male), and 1452 had cirrhosis (mean [SD] age, 66.99 [7.09] years; 1360 [93.7%] male) at baseline. These patients were matched to an equal number of patients who initiated a DPP-4i. In patients without cirrhosis, GLP-1 RA use, compared with DPP-4i use, was associated with a lower risk of cirrhosis (9.98 vs 11.10 events per 1000 person-years; hazard ratio [HR], 0.86; 95% CI, 0.75-0.98). Similar results were seen for the secondary outcomes. GLP-1 RA use, compared with DPP-4i use, was associated with a lower risk of the composite outcome of cirrhosis complications (1.89 vs 2.55 events per 1000 person-years; HR, 0.78; 95% CI, 0.59-1.04) and mortality (21.77 vs 24.43 events per 1000 person-years; HR, 0.89; 95% CI, 0.81-0.98). There were no associations between GLP-1 RA use and outcomes in patients with cirrhosis. Conclusions and Relevance In this cohort study, GLP-1 RA use was associated with a lower risk of progression to cirrhosis and mortality among patients with MASLD and diabetes. The protective association was not seen in patients with existing cirrhosis, underscoring the importance of treatment earlier in the disease course.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
传奇3应助蒸蒸日上采纳,获得10
2秒前
库里强发布了新的文献求助10
2秒前
3秒前
4秒前
4秒前
4秒前
zzz发布了新的文献求助10
5秒前
ElbingX发布了新的文献求助50
6秒前
7秒前
8秒前
晓昀发布了新的文献求助10
8秒前
9秒前
鸢尾应助狂野的白开水采纳,获得10
9秒前
9秒前
10秒前
科研通AI2S应助科研通管家采纳,获得10
10秒前
天天快乐应助科研通管家采纳,获得10
10秒前
tfq200发布了新的文献求助10
10秒前
orixero应助科研通管家采纳,获得10
10秒前
领导范儿应助科研通管家采纳,获得10
10秒前
深情安青应助科研通管家采纳,获得10
10秒前
10秒前
CipherSage应助科研通管家采纳,获得10
10秒前
zqh应助科研通管家采纳,获得10
10秒前
科研通AI2S应助科研通管家采纳,获得10
10秒前
科研通AI2S应助科研通管家采纳,获得10
10秒前
10秒前
11秒前
11秒前
qq完成签到,获得积分10
11秒前
11秒前
胖柠檬给胖柠檬的求助进行了留言
12秒前
13秒前
13秒前
13秒前
13秒前
小样发布了新的文献求助10
14秒前
qq发布了新的文献求助10
14秒前
连渡完成签到,获得积分10
14秒前
高分求助中
Sustainability in ’Tides Chemistry 2000
Sustainability in ’Tides Chemistry 1500
Studien zur Ideengeschichte der Gesetzgebung 1000
The ACS Guide to Scholarly Communication 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3071903
求助须知:如何正确求助?哪些是违规求助? 2725788
关于积分的说明 7491264
捐赠科研通 2373147
什么是DOI,文献DOI怎么找? 1258476
科研通“疑难数据库(出版商)”最低求助积分说明 610277
版权声明 596944